Stifel Maintains Hold on Health Catalyst, Lowers Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst David Grossman has maintained a 'Hold' rating on Health Catalyst (NASDAQ:HCAT) and lowered the price target from $15 to $12.
November 01, 2023 | 7:34 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Stifel analyst David Grossman has maintained a 'Hold' rating on Health Catalyst and lowered the price target from $15 to $12.
The lowering of the price target by Stifel analyst David Grossman from $15 to $12 indicates a bearish outlook for Health Catalyst. This could potentially lead to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100